Hepion Pharmaceuticals, Inc. (HEPA) Social Stream



Hepion Pharmaceuticals, Inc. (HEPA): $0.70

0.01 (+0.82%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add HEPA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#262 of 358

in industry

Featured Post From StockTwits About HEPA

$HEPA “As for Phase 2 trials it consists of two parts, Phase 2A and Phase 2B. Phase 2A objectives include the safety and tolerability of the 75 mg and 225 mg doses of CRV431 taken daily in the Fibrosis stage 2 (F2)/fibrosis stage 3 (F3) patients for NASH. These patients are also compared to placebo control for 28 days. Two other goals of this phase were to explore biomarkers of fibrosis and lipids metabolism: lipidomics, collagens, genomics, matrix metalloproteinases and also to multi-omic/trait data analysis by AI-POWR. As for Phase 2B the main focus is on efficacy of the 75 mg and 225 mg doses of CRV431 in NASH F2 and F3 patients proven through biopsy. These patients are compared to placebo with over 6 months of dosing. Another objective in this study is to gain a 1-point reduction in the fibrosis score of their liver biopsies. The company also intends on using its AI-POWR system to identify biomarkers of CRV431 from clinical labs, multi-omics, and other trait data.”
OG13Jacket, published August 7, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!